Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis
about
Schiff base-mediated co-stimulation primes the T-cell-receptor-dependent calcium signalling pathway in CD4 T cellsNovel compounds active against Leishmania major.Clinical and experimental advances in treatment of visceral leishmaniasis.Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.Discovery of immunopotentiatory drugs: current and future strategies.L-Asparaginase as a new molecular target against leishmaniasis: insights into the mechanism of action and structure-based inhibitor design.Current diagnosis and treatment of visceral leishmaniasis.Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos.Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art.Adjunct effect of immunostimulating hexapeptide analogous to human beta-casein fragment (54-59) to sodium stibogluconate against experimental visceral leishmaniasis.Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones.A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.Leishmania recombinant antigen modulates macrophage effector function facilitating early clearance of intracellular parasites.In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.
P2860
Q28360447-0344A8FC-A745-4EC5-8E7A-F1706B3000A5Q30807168-8F8D5EA2-A8B5-4829-BC4D-75EEA38107D0Q33982648-22F1C89A-E93D-4D0B-9483-236CA0C39AF7Q34054948-AC8D5DCC-DCF5-4A42-8094-3E136FD22C01Q35009482-A261F5CA-BDB3-4662-8262-5B6FFC6EE0B0Q35609857-638502A0-0CFD-43CC-A383-5CD2B2311B18Q37778829-DD243375-4D13-41A0-95AC-2D8679C23785Q38154629-EA7226B6-B4D4-4C38-9649-D67400C86547Q38939544-1E3C3489-7958-4FF8-8D71-DB4CE12BCDD5Q39037436-D46C35B2-01DE-481C-B146-02CA876F58C2Q39477746-BE98D11E-BFF5-46E5-8E2D-94D30308827AQ40222476-854856B5-0A93-4A21-BF99-E9BD3DF8D300Q40414188-EC605772-24F1-46EE-8C28-8C12B2DE387AQ41844113-1985A6C4-DF6C-4FBB-92DB-0D57438511D6Q41990715-328E1066-D543-4FA4-BD0E-711AC8DF40C5
P2860
Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Activity of the novel immunomo ...... imental visceral leishmaniasis
@ast
Activity of the novel immunomo ...... imental visceral leishmaniasis
@en
type
label
Activity of the novel immunomo ...... imental visceral leishmaniasis
@ast
Activity of the novel immunomo ...... imental visceral leishmaniasis
@en
prefLabel
Activity of the novel immunomo ...... imental visceral leishmaniasis
@ast
Activity of the novel immunomo ...... imental visceral leishmaniasis
@en
P2093
P2860
P1476
Activity of the novel immunomo ...... imental visceral leishmaniasis
@en
P2093
P2860
P304
P356
10.1128/AAC.44.6.1494-1498.2000
P407
P577
2000-06-01T00:00:00Z